Head to Head Survey: SOPHiA GENETICS (NASDAQ:SOPH) vs. DIAGNOS (OTCMKTS:DGNOF)
by Tristan Rich · The Markets DailySOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) and DIAGNOS (OTCMKTS:DGNOF – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.
Analyst Ratings
This is a summary of current recommendations and price targets for SOPHiA GENETICS and DIAGNOS, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SOPHiA GENETICS | 1 | 1 | 3 | 0 | 2.40 |
| DIAGNOS | 0 | 0 | 0 | 0 | 0.00 |
SOPHiA GENETICS currently has a consensus price target of $10.00, indicating a potential upside of 22.85%. Given SOPHiA GENETICS’s stronger consensus rating and higher probable upside, analysts plainly believe SOPHiA GENETICS is more favorable than DIAGNOS.
Institutional and Insider Ownership
31.6% of SOPHiA GENETICS shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
SOPHiA GENETICS has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Comparatively, DIAGNOS has a beta of -0.11, suggesting that its stock price is 111% less volatile than the S&P 500.
Valuation and Earnings
This table compares SOPHiA GENETICS and DIAGNOS”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SOPHiA GENETICS | $86.17 million | 7.93 | -$79.00 million | ($1.15) | -7.08 |
| DIAGNOS | $50,000.00 | 871.25 | -$3.30 million | ($0.04) | -9.00 |
DIAGNOS has lower revenue, but higher earnings than SOPHiA GENETICS. DIAGNOS is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares SOPHiA GENETICS and DIAGNOS’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SOPHiA GENETICS | -93.86% | -132.47% | -45.97% |
| DIAGNOS | -7,014.89% | N/A | -192.10% |
Summary
SOPHiA GENETICS beats DIAGNOS on 10 of the 14 factors compared between the two stocks.
About SOPHiA GENETICS
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.
About DIAGNOS
DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. DIAGNOS Inc. was founded in 1998 and is headquartered in Brossard, Canada.